[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of California, Los Angeles\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":713},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,174,0,25,[9,49,82,108,133,159,181,209,235,262,284,313,336,364,397,430,455,479,506,539,564,588,631,664,687],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100605889","pre-emptive-rto-for-an-early-detected-gastric-varices-in-ctmr-angiogram-trial-100605889",false,"NCT07168395","Pre-emptive RTO for An Early Detected Gastric Varices in CT\u002FMR Angiogram Trial","Pre-emptive RTO for An Early Detected Gastric Varices in CT\u002FMR Angiogram Trial (PRADA Trial)","PRADA","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Patients with compensated cirrhosis with a higher risk of decompensation based on AASLD 2023 Practice Guidance (Kaplan et al) - no ascites with endoscopic visualization of varices\n3. Confirmed diagnosis of gastric varices either through CT, MRI, or Endoscopy.\n4. No imaging (LIRAD4 or 5) or tumor marker (AFP) evidence of HCC or other malignancy\n5. MELD \\\u003C 20\n6. First de novo RTO procedure\n7. Taking NSBB\n8. Patent internal jugular or right common femoral vein\n9. Willing to provide the hepatology service information for F\u002FU\n10. No known diagnosis of hypercoagulopathy\n11. Patent portal vein or portal vein cavernous transformation\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Patients with decompensated cirrhosis based on AASLD 2023 Practice Guidance (Kaplan et al)\n3. Cardiac failure\n4. Active variceal bleeding\n5. History of gastroesophageal variceal bleeding\n6. Previous TIPS, BRTO, CARTO or PARTO procedure\n7. No right jugular or right common femoral venous access\n8. No portal vein flow\n9. Malignancy\n10. Life expectancy of less than 6 months","ALL","18 Years",{"count":21,"type":22},68,"ESTIMATED","INTERVENTIONAL",[25],"NA","A number of treatment modalities are currently in use for gastric variceal bleeding (GVB). Balloon-occluded, plug-assisted, and coil-assisted retrograde transvenous obliteration (RTO) procedures are described in the literature as treatments for GVB after a bleeding episode occurs. Preliminary data suggests that prophylactic treatment of gastric varices may improve patient outcomes compared to conservative management. This study aims to compare pre-emptive treatment of gastric varices with current recommended medical management in a randomized prospective study design. Eligible patients will be randomized to receive RTO or to continue conservative management. Patients will be followed for up to 2 years for comparison of clinical outcomes, including episodes of gastric variceal bleeding, overall survival and transplant-free survival, complications, and secondary interventions.",[28],"Gastric Varices",[30,31,32,33,34,35,36],"varices","stomach","gastric","hepatic encephalopathy","gastric variceal bleeding","bleeding","retrograde transvenous obliteration","NOT_YET_RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":22},"2026-10",{"date":45,"type":22},"2028-11",{"name":47,"class":48},"University of California, Los Angeles","OTHER",{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100590067","mentor-moms-study-100590067","NCT06962592","Mentor Moms+ Study","A Community-based Adaptation of a Peer-led Intervention to Address Alcohol Use and HIV Risk in Pregnant Women in South Africa (Mentor Moms+)","(MM+)","Inclusion Criteria:\n\n* • ≥ 16 years;\n\n  * Pregnancy confirmed;\n  * reported alcohol use during pregnancy (in last 2 months);\n  * lives within 20 kilometers of the study facility;\n  * able and willing to consent to study participation.\n\nExclusion Criteria:\n\n* Individuals not meeting the above criteria will be excluded.",true,"FEMALE","16 Years",{"count":61,"type":22},100,[25],"The goal of this study is to adapt an existing evidence based intervention for use in pregnant and lactating people (PLP) who use alcohol. Through the pilot RCT, we aim to understand if tailored intervention, Mentor Mothers+, is effective in reducing alcohol use (primary outcome) and improving antiretroviral (PrEP or ART) adherence (secondary outcomes) among pregnant and breastfeeding women living with and without HIV in a community heavily burdened by this syndemic.\n\nThe investigators will conduct an pilot randomized control trial in 100 pregnant women, recruited during antenatal care (ANC) visits within the Saldanha Bay Municipality clinic in Cape Town, South Africa. The RCT will involve the delivery of brief, individual motivational interviewing sessions provided by trained mentor mothers from the community who are on either PrEP (living without HIV) or ART (living with HIV) and who stopped or reduced alcohol use during pregnancy. The enrolled participants will be followed for a 6-month period spanning both pregnancy and postpartum stages.",[65,66],"HIV","Alcohol Consumption",[68,69,70,71,72,73],"pregnant","postpartum","HIV prevention","HIV treatment","Alcohol use","breastfeeding","RECRUITING",{"date":40,"type":41},{"date":77,"type":41},"2025-09-01",{"date":79,"type":22},"2027-08-31",{"name":47,"class":48},2,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100568530","telerehabilitation-in-the-home-after-stroke-100568530","NCT06682429","Telerehabilitation In The Home After Stroke","Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial","TR-2","Inclusion Criteria:\n\n1. Age 18-80 years at the time of randomization\n2. The index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 120±30 days prior to randomization\n3. The stroke caused upper extremity deficits as defined by Action Research Arm Test score 18-44 (out of 57) at Baseline Visit 1\n4. Box \\& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit 1\n5. Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit 1\n6. Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent)\n\nExclusion Criteria:\n\n1. A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures\n2. Unable or unwilling to perform study procedures\u002Ftherapy, or expectation of noncompliance with study procedures\u002Ftherapy, or expectation that subject cannot participate in all study visits\n3. A diagnosis (apart from the index stroke) that substantially affects paretic arm function\n4. Severe depression, defined as Geriatric Depression Scale Score \\>10\u002F15 at Baseline Visit 1\n5. Significant cognitive impairment, defined as Montreal Cognitive Assessment score \\\u003C22 \\[a lower score is permitted if due to aphasia and allowed by the site PI\\]\n6. Deficits in communication that interfere with reasonable study participation\n7. Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis\n8. Modified Rankin Scale score was \\>2 prior to the index stroke\n9. A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke\n10. Lacking visual acuity, with or without corrective lens, of 20\u002F50 or better in at least one eye\n11. Life expectancy \\\u003C 9 months\n12. Pregnant; women of child-bearing potential must have a negative pregnancy test\n13. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected by the 8-Month Visit\n14. Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study\n15. Subject lacks sufficient English or Spanish to comply with study procedures and TR instructions\n16. Expectation that subject will not have a single domicile address during the 6 weeks of therapy that is within 1.5-hr drive of the central study site \\[this can be waived at the discretion of the site PI\\]\n17. Contraindication to MRI\n18. On isolation precautions, e.g., due to active COVID-19","80 Years",{"count":92,"type":22},202,[25],"The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.\n\nPatients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: \\[1\\] TR and usual care; \\[2\\] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes\u002Fday of activities targeting arm function, 6 days a week for 6 weeks.",[96],"Stroke",[98,99,100],"stroke","rehabilitation","telehealth",{"date":40,"type":41},{"date":103,"type":41},"2025-08-22",{"date":105,"type":22},"2030-06",{"name":47,"class":48},27,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":81},"100512527","phase-2-endotypic-traits-and-obstructive-sleep-apnea-surgery-100512527","NCT05953610","Endotypic Traits and Obstructive Sleep Apnea Surgery","Inclusion criteria are:\n\n1. age ≥21 years;\n2. moderate to severe OSA (obstructive AHI ≥ 15 events\u002Fhour);\n3. central\u002Fmixed apnea index \\\u003C5 events\u002Fhour;\n4. intolerance of positive airway pressure (defined as use \\\u003C 2 hours\u002Fnight at least 5 nights\u002Fweek);\n5. intolerance or poor candidate for oral appliance;\n6. participant has provided informed consent for palate surgery as part of their standard of care;\n7. tonsil size 0-2+ (without markedly enlarged tonsils that have high surgical success rates);\n8. DISE without evidence of complete tongue-related obstruction (reflecting poorer results with isolated palate surgery);\n9. medications stable for ≥2 months;\n10. body mass index \\\u003C35 kg\u002Fm2;\n11. absence of uncontrolled nasal obstruction;\n12. no prior pharyngeal surgery other than tonsillectomy;\n13. no neurologic, cardiac or pulmonary disorders;\n14. absence of psychiatric disorder except for treated depression or mild anxiety;\n15. no co-existing sleep disorder, such as narcolepsy, chronic insomnia, or restless legs syndrome;\n16. no use of hypnotics, anxiolytics, stimulants, or sedating antidepressants;\n17. no near-miss or prior motor vehicle crash due to sleepiness in past 12 months; and\n18. \\\u003C3 caffeinated beverages daily.\n\nExclusion criteria are:\n\n1. history of allergic reaction to either of the study drugs;\n2. subjects with prior serious allergic reaction (such as Stevens-Johnson syndrome) to sulfonamides;\n3. subjects with a history of hypersensitivity to either of the two study drugs;\n4. subjects who are on high-dose aspirin therapy due to risk of severe metabolic acidosis;\n5. subjects with severe kidney disease or severe liver disease;\n6. subjects with a history of electrolyte imbalance or adrenal insufficiency (due to risks related to acetazolamide);\n7. subjects on ketoconazole or other strong CYP3A4 inhibitors (these will increase eszopiclone blood levels);\n8. pregnancy; and\n9. alcohol or substance abuse.","21 Years",{"count":116,"type":22},150,[118],"PHASE2","This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).",[121],"Obstructive Sleep Apnea",[123,124,125],"surgery","loop gain","arousal threshold","2026-06-29",{"date":38,"type":41},{"date":129,"type":41},"2024-01-07",{"date":131,"type":22},"2028-08-31",{"name":47,"class":48},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":81},"100489513","comparing-surgical-and-endovascular-arteriovenous-fistula-creation-100489513","NCT05654103","Comparing Surgical and Endovascular Arteriovenous Fistula Creation","Randomized Controlled Trial Comparing endoAVF Versus surgAVF","Inclusion Criteria:\n\n* ESKD patients aged ≥ 18 who have chosen hemodialysis as their renal replacement option.\n* Ability to give consent to participate in a research study.\n* Upper arm vein diameter of ≥ 2.0 mm.\n\nEllipsys specific inclusion criteria:\n\n* Confirmed radial artery-adjacent vein proximity ≤ 1.5 mm measured lumen edge-to-lumen edge as determined by preprocedural ultrasound and confirmed pre-procedurally.\n* Confirmed radial artery and adjacent vein diameter of ≥ 2.0 mm at site where vein and artery connects.\n\nWavelinQ specific inclusion criteria:\n\n* Target vein diameter ≥ 2.0 mm, target artery diameter ≥ 2.0 mm, and ≤ 2 mm between target artery and vein.\n\nExclusion Criteria:\n\n* People under the age of 18.\n* Inability to understand the consent process and\u002For give consent.\n* Upper arm vein diameter less than 2.0 mm making them unsuitable to receive an surgAVF AND endoAVF.\n* Patients who are deemed by the surgeon to be anatomic candidates for a forearm vascular access, and the surgeon and the patient determine that a forearm access is the optimal access for the patient, in order to preserve more proximal anatomic sites for future accesses.\n* Currently incarcerated individuals.\n* Currently pregnant or planning to get pregnant within the next 6 months.\n* Individuals who choose peritoneal dialysis over hemodialysis and\u002For undergoing a kidney transplant within 6 months of randomization.","99 Years",{"count":142,"type":22},90,[25],"Patients with end-stage kidney disease (ESKD) who use hemodialysis to filter their blood require vascular access for the dialysis machine; the most common type of vascular access is called an arteriovenous fistula (AVF). The AVF is a direct connect between an artery and vein.\n\nUntil recently, AVFs were only created through surgery that requires general anesthesia and opening up the skin. Now there are 2 FDA-approved devices designed to create AVFs using endovascular techniques (endoAVF), which means a device that goes through the skin instead of opening the skin up. Also patients are not required to be under general anesthesia, they can receive local anesthesia instead. Due to the relatively new approval of these devices, there is not a randomized study to compare the results of endoAVF versus surgAVF.\n\nThis study is a pilot study for an eventually larger scale study to compare the results of endoAVF versus surgAVF. The study aims to determine what the proportion of patients seeking hemodialysis access could qualify for receiving either an endoAVF , surgAVF, or both. Patients who are screened for hemodialysis access must undergo a duplex ultrasound of the blood vessels in the arm to confirm correct sizing. If participants qualify for both procedures they will be randomized to either endoAVF or surgAVF and will track the clinical and patient-reported outcomes of each procedure. Our pilot study hopes to enroll 90 participants. Those outcomes will inform a larger scale study. If the potential participant chooses to abstain from participation in the randomized trial, preferring to decide the method of AVF creation, we will offer to them a chance to join an endoAVF\u002FsurgAVF registry that will track the clinical outcomes of the procedure via medical record monitoring.",[146],"End Stage Renal Disease on Dialysis",[148,149,150,151,152],"hemodialysis","arteriovenous fistula","fistula","endoAVF","End Stage Renal Disease",{"date":38,"type":41},{"date":155,"type":41},"2024-11-20",{"date":157,"type":22},"2028-01-01",{"name":47,"class":48},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},"100109911","phase-2-drug-induced-sleep-endoscopy-for-upper-airway-evaluation-in-obstructive-sleep-apnea-100109911","NCT00695214","Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Adult patients with OSA considering surgical treatment\n\nExclusion Criteria:\n\n* Minors\n* Pregnant women\n* Patients unable to provide informed consent in English themselves\n* Prisoners\n* Allergy to propofol, soybean oil, egg lecithin or glycerol\n* Other contraindication to use of propofol (decision of anesthesiologist or otolaryngologist.)",{"count":166,"type":22},800,[118],"Prospective, interventional cohort study of drug-induced sleep endoscopy (DISE) to evaluate the upper airway in a cohort of obstructive sleep apnea (OSA) surgical patients. This study has investigated the reliability of this technique, demonstrating moderate-substantial interrater and test-retest reliability. This research has also compared DISE findings to those of the lateral cephalogram X-ray and examined DISE findings in individuals who have not responded to previous sleep apnea surgery. These papers have been published and available through PubMed. Additional research is ongoing, with examination of DISE findings, comparison to other evaluation techniques, and the association between DISE findings and surgical outcomes.",[170],"Sleep Apnea, Obstructive",[121,172,173],"Propofol","Sleep Endoscopy",{"date":38,"type":41},{"date":176,"type":41},"2004-02",{"date":178,"type":22},"2035-06",{"name":47,"class":48},1,{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":199,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":208,"locationsCount":4},"100644755","a-two-part-intervention-to-target-cardiovascular-health-100644755","NCT07673172","A Two-Part Intervention to Target Cardiovascular Health","Autism Research Consortium on Physical Health: A Two-Part Intervention to Target Cardiovascular Health","Inclusion Criteria:\n\n* • Have a diagnosis of autism or be told by a healthcare provider that you have autism\n\n  * Be between the ages of 9 and 26\n  * Have a BMI greater than the 84th percentile\n  * English speaking\n\nExclusion Criteria:\n\n* • Children younger than 9 years of age\n\n  * Adults older than 26 years of age\n  * Individuals without a diagnosis of autism\n  * Individuals with a BMI less than the 84th percentile","9 Years","26 Years",{"count":191,"type":22},130,[25],"Obesity is one of the most common health conditions among autistic young people and its prevalence rises at faster rates for autistic-relative to non-autistic-individuals. This places them at heightened risk for cardiovascular disease (CVD) and mortality before they enter adulthood. Studies have identified three key contributing factors to CVD outcomes in autistic individuals: unhealthy lifestyle behaviors, Adverse Childhood Experiences (ACEs), and chronic stress.\n\nThis study will explore the effectiveness of two CVD-focused primary care interventions for autistic individuals (ages 9-26): (1) lifestyle medicine consultations tailored towards supporting health-promoting behaviors; and (2) a Cognitive Behavioral Therapy (CBT) intervention tailored towards addressing chronic stress that contributes to excess weight and maladaptive eating behaviors and results in obesity and CVD. Participants and their caregivers will be randomly placed into either the Lifestyle Medicine Group, CBT Group, or combined Lifestyle Medicine with CBT Group. Participants will respond to questionnaires and surveys measuring lifestyle habits, stress, and psychological risk factors at their first visit, 6-month visit, and 3 months post-intervention visit. Over the course of 6 months, participants will attend virtual sessions (up to three times a month) in accordance with their intervention group.",[195,196,197,198],"Autism","Adverse Childhood Experience","Stress","Cardiovascular (CV) Risk",[200,201,202,203],"autism","adverse childhood experiences","stress","cardiovascular risk","2026-06-22",{"date":126,"type":41},{"date":38,"type":22},{"date":131,"type":22},{"name":47,"class":48},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":234,"locationsCount":180},"100644486","applying-the-intention-action-framework-to-specialty-referrals-100644486","NCT07671976","Applying the Intention-Action Framework to Specialty Referrals","Reducing Low-Value Care: Applying the Intention-Action Framework to Specialty Referrals","Inclusion Criteria:\n\n* UCLA Health physicians who have made at least one specialty referral to cardiology, pulmonology, or gastroenterology for patients in UCLA Health primary care registry during July-December 2025\n\nExclusion Criteria:\n\n* Physicians who are no longer actively practicing at UCLA Health as of July 1, 2026",{"count":217,"type":22},1600,[25],"This is a prospective randomized controlled trial evaluating an EHR-embedded behavioral intervention intended to reduce low-value specialty referrals in cardiology, pulmonology, and gastroenterology. The intervention is designed to (1) strengthen physicians' intentions to avoid low-value specialty referrals at the point of encounter by presenting criteria for high-value referrals and informing physicians that referral decisions may be reviewed and (2) support follow-through on these intentions by modifying the referral process through structured checklist prompts embedded within the referral workflow.\n\nThe primary hypothesis is that physicians exposed to the intervention will demonstrate lower rates of low-value cardiology, pulmonology, and gastroenterology referrals compared with physicians exposed to the arm where the order composer allows physicians to place referrals with minimal decision support.",[221,222,223],"Cardiology","Gastroenterology","Pulmonology",[225,226,227,228,221,223,222],"Low-value referral","Behavioral science","Physician decision-making","Quality improvement",{"date":230,"type":41},"2026-06-26",{"date":38,"type":22},{"date":233,"type":22},"2027-01-31",{"name":47,"class":48},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":245,"phases":4,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":180},"100528600","single-time-point-prediction-as-earlier-diagnosis-of-progressive-pulmonary-fibrosis-100528600","NCT06162884","Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis","Imaging Signature of Progressive Pulmonary Fibrosis in Idiopathic Pulmonary Fibrosis and Non-IPF Interstitial Lung Diseases","IS-PPF","IPF Inclusion Criteria:\n\n* Established a diagnosis (within 5 years) of IPF by enrolling center as defined by ATS\u002FERS\u002FJRS\u002FALAT criteria\n* Age over or equal to 40 years old\n* No history of lung transplant\n* FVC % predicted \\>= 45%\n* DLCO % predicted \\>=25%\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control. WOCBP taking oral contraceptives (OCs) also have to use one barrier method.\n\nNon-IPF ILD Inclusion Criteria:\n\n* Established a diagnosis (within 5 years) of non-IPF ILD by enrolling center.\n* Age over or equal to 18 years old\n* Presence of chronic fibrosis ILD defined as architectural distortions with reticulation and the presence of traction bronchiectasis by visual assessment: (1) estimating visually \\>5% in whole lung, or (2) mild pulmonary fibrosis and \\\u003C5% in whole lung (i.e., early non-IPF-ILD identified by a pulmonologist).\n* Patients treated with immunosuppressive agents (other than corticosteroids) for an underlying systemic disease need to be on a stable treatment for at least 12 weeks prior to screening\n* FVC % predicted \\>= 45%\n* DLCO % predicted \\>=25%\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control. WOCBP taking oral contraceptives (OCs) also have to use one barrier method\n\nExclusion Criteria:\n\n* Planned to participate in an intervention trial within the next 6 months\n* Currently listed for lung transplantation at the time of enrollment\n* Malignancy, treated or untreated, other than malignancy unlikely to affect prognosis in the next 3 years such as skin cancer or non-metastatic prostate cancer within the past 5 years\n* Any clinically significant co-morbidity, which in the view of investigator, is likely to contribute to mortality or ability to perform PFT's in the next 2 years\n* Prebronchodilator Forced Expiratory Volume in 1 second (FEV1)\u002FForced vital capacity (FVC) \\\u003C0.7 at as screening\n* Exclusion of co-morbidities: congestive heart failure (stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction), current virus-associated community acquired pneumonia, smoking-related chronic obstructive lung disease with FEV1 \\\u003C70%, history of lung cancer, history of other cancer treated within the past 4 years for IPF and 5 years for non-IPF ILD (excluding basal cell carcinoma of skin).\n\nHRCT data from subjects with combined pulmonary fibrosis and emphysema (CPFE) can be collected.\n\nMajor Discontinuing Criteria in this study\n\n* lung transplant after baseline or death\n* withdraw of consent or transition to another care center",{"count":244,"type":22},200,"OBSERVATIONAL","This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD).\n\nThe purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc\u002F machine learning (AI\u002FML) using the radiomic features from a HRCT scan that quantifies the imaging patterns of short-term predictive worsening.",[248],"Pulmonary Fibrosis",[250,251,252,253],"imaging outcome","Single Timepoint Prediction","AI\u002Fmachine learning","progressive ILD","2026-06-16",{"date":256,"type":41},"2026-06-18",{"date":258,"type":41},"2024-11-06",{"date":260,"type":22},"2029-08-19",{"name":47,"class":48},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":283},"100473987","a-dyadic-sleep-health-approach-for-persons-with-alzheimers-disease-and-caregivers-100473987","NCT05452031","A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers","A Dyadic Approach to Improve Sleep and Well-Being Among Persons With Alzheimer's Disease and Their Caregivers","Inclusion Criteria for Patients\n\n* Have a diagnosis of Alzheimer's disease (probable or possible) or other related dementia as documented in an electronic medical record\n* Community-dwelling\n* \\>1 sleep problems \\>3x\u002Fweek on the Neuropsychiatric Inventory Nighttime Behavior Scale, - - Aged \\>60 years\n* Have no untreated sleep disorders (e.g., sleep apnea, restless legs syndrome)\n* Able to ambulate with or without assistive devices (i.e., dyads will be excluded if the care recipient is bedbound)\n* Have no severe medical conditions with a life expectancy of less than 6 months\n* Have an eligible caregiver\n\nInclusion Criteria for Caregivers\n\n* Live with an eligible patient\n* Aged \\>18 years\n* Is related to the patient as a family member, a significant other, or a friend\n* Have regularly assisted patient with \\>1 of 6 basic activities of daily living (ADLs; i.e., bathing, dressing, toileting, transferring, continence, feeding) or \\>1 of 8 Instrumental ADL (IADLs; i.e., using the telephone, shopping, food preparation, housekeeping, laundry, transportation, taking medications, managing money) for the past 6 months\n* Pittsburgh Sleep Quality Index (PSQI) total score \\>5\n* Montreal Cognitive Assessment (MoCA) ≥23\n* Can communicate in English\n\nExclusion Criteria:\n\n* Patients will be excluded if they are bedbound or have severe medical conditions with a life expectancy of less than 6 months.\n* Paid, professional caregivers will also be excluded.\n* If the eligibility criteria for either a patient or a caregiver are not met, the dyads will be excluded for this study.",{"count":270,"type":22},672,[25],"This is a randomized controlled trial over 5 years, using Stage II of the NIH-defined stage model for behavioral intervention development. We will evaluate the efficacy of the sleep intervention program (Care2Sleep) on sleep, health status measures, and quality of life (for dyads), and inflammation (for caregivers only). Eligible participants will be randomly assigned to in-person Care2Sleep, telehealth Care2Sleep, or to an in-person education control group. The Care2Sleep programs and the control education program will consist of five sessions. The intervention and control programs will begin after baseline assessment and randomization. Posttreatment assessments will be performed immediately after the last session and at 6-month follow-up.",[274],"Sleep",[276,277],"Dementia","Caregivers",{"date":256,"type":41},{"date":280,"type":41},"2022-11-09",{"date":79,"type":22},{"name":47,"class":48},3,{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":57,"sex":18,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":180},"100555066","polyphenols-and-cognitive-decline-100555066","NCT06507254","Polyphenols and Cognitive Decline","MAEVE: Microbiota Mediated Flavonoid Metabolites for Cognitive Health","MAEVE","Inclusion Criteria:\n\n* 50+ Years of age\n* Male or Female\n* At enhanced risk of Alzheimer's Disease (defined as family history of AD, 1st degree family member)\n* Habitually consume suboptimal diets such as typical Western Diet (i.e., high in animal products, refined carbohydrates and processed food)\n* Able to communicate well in English\n\nExclusion Criteria:\n\n* Vegan or Vegetarian\n* Presence of cognitive impairment at the time of recruitment into the study as measured by the Mini Mental Status Exam (MMSE, score 25-30) and Clinical Dementia Rating (CDR, score=0).\n* Pre-existing psychosis or psychiatric conditions\n* Currently receiving treatment for dementia\n* History of alcohol and\u002For substance abuse\u002Fdependence as determined by a positive endorsement on the MINI+\u002F If the MINI+ is positive for alcohol or drug dependence, or abuse, the participants will be excluded.\n* Heavy use of tobacco (greater than 1\u002F2 pack per day)\n* History of cerebrovascular events\n* Existing allergies to berry fruits\n* Use of oral\u002FIV antibiotics in the last 3 months. Use of probiotics in the last 1 month.\n* Recent Changes (last 3 months) in the use of psychoactive medications or other medications that interfere with the measured outcomes.\n* Frailty, malnutrition, or food allergy\u002Fintolerance requiring special diets.\n* Body weight at enrollment greater than 400lbs due to weight restrictions on the MRI table.\n* Women who are pregnant, lactating, or postpartum for less than 6months.\n* Women of childbearing age who are not practicing birth control or are planning to get pregnant during the study.\n\nUnable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, metallic foreign body, etc.)\n\n* Chronic Pain","50 Years",{"count":294,"type":22},300,[25],"Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent cognitive decline. A traditional Mediterranean diet, rich in polyphenols (PPs), may prevent or delay the onset of cognitive dysfunction in older adults, preserving healthy brain structure and function, and lowering the risk of AD. These effects, mediated in part by gut microbiome-derived PP metabolites, highlight the role alterations in the brain-gut microbiome system play in neurodegeneration. Moreover, high levels of circulating phenyl-y-valerolactones, neuroprotective compounds, exclusively produced by gut microbiota from flavan-3-ol-rich foods (e.g., cocoa, tea, berries) are associated with delaying the onset of cognitive dysfunction in older adults. Intake of such PPs can also change gut microbial composition and function, altering the physiology of the hosts secondary bile acid (BA) pool, affecting regulatory and signaling functions in the brain as well as cognitive decline and AD. The investigators hypothesize that, in older adults with enhanced AD risk, dietary intake of PPs maintains healthier brain features and cognitive function, and that this beneficial effect is mediated by gut microbiota metabolites of PPs and BAs.\n\nIn this multi-PI application by leaders in the field of brain-gut microbiome interactions, the investigators will conduct a year-long, multi-center, randomized double-blind placebo-controlled study in 300 older adults in the United States (validation sample of 100 from Northern Ireland) who are at enhanced risk of developing AD. Ultimately, the investigators will establish the protective effects of regular dietary PP intake on cognitive function and on brain-gut microbiome interactions, ideally allowing the development of effective dietary regimes to prevent of delay the onset of AD in at-risk elderly, thereby reducing cognitive decline and healthcare costs.\n\nParticipants will be asked to provide information about their diet, mood, and behaviors via food diaries, physical body measures (e.g. height, weight, etc.), and online questionnaires collected before each in-clinic appointment, as well as monthly online questionnaires. MR imaging will be collected on participants to assess neurocognitive changes as a result of the supplement. Participants will be asked to provide both stool and blood samples. Participants will be randomly assigned to either the Juice Plus+ intervention group or the placebo treatment group and then asked to take their respective supplement 4 pills twice a day. All participants will be asked to come in for 4 in-clinic appointments, including 3 brain MRI scans and 3 cognitive testing appointments, collect 3 stool samples with corresponding diet diaries, and provide 3 blood samples over the course of 12 months. Participants will also meet with a nutritionist 3 times over the 12 months to discuss diet to ensure study eligibility and any questions about the supplement.",[298,299],"Cognitive Decline","Cognitive Dysfunction",[301,302,303,304],"Polyphenols","Mediterranean Diet","Gut Microbiome","Alzheimers Disease","2026-06-09",{"date":307,"type":41},"2026-06-11",{"date":309,"type":41},"2025-01-09",{"date":311,"type":22},"2029-12-31",{"name":47,"class":48},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":57,"sex":18,"minAge":321,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":245,"phases":4,"briefSummary":324,"conditions":325,"keywords":329,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":180},"100479078","platelet-expression-of-fcriia-and-arterial-hemodynamics-to-predict-recurrent-stroke-in-intracranial-atherosclerosis-100479078","NCT05518305","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosi","FCG","Inclusion Criteria:\n\n* Stroke is defined as symptoms lasting \\>24 hours and associated with imaging evidence of acute ischemia in the distribution of the stenotic vessel on head CT or brain MRI. Minor stroke is defined as NIHSS\\\u003C6, as used in prior studies.\n* Eligible TIA, defined as transient neurological symptoms lasting \\\u003C24 hours, need to be: a) accompanied by DWI abnormalities in the distribution of the stenotic artery; or b) multiple (\\>1), stereotyped events associated with unequivocal ischemic symptoms (i.e. weakness, aphasia, diplopia), and attributed to the symptomatic artery. The intent of these restrictive inclusion criteria for TIA is to exclude potential stroke mimics.\n* ICAD should involve the intracranial carotid, middle cerebral, intracranial vertebral or basilar arteries. Isolated anterior and posterior cerebral artery stenosis is not included as it is uncommon in these locations and non-invasive criteria for high-grade ICAD are not well established for these vessels.\n* Stenosis 50-99% will be quantified by CTA. The criteria for 50-99% are: measured stenosis by WASID criteria (percent stenosis = (1-\\[diameter stenosis\u002Fdiameter normal\\]) x 100%.\n* Age ³30; those 30-49 years of age must also have the presence of established atherosclerotic disease in another vascular bed (coronary, extracranial carotid, peripheral) or the presence of 2 or more risk factors (hypertension, diabetes mellitus, hyperlipidemia, tobacco abuse within the last 2 years). The rationale for this criterion is to exclude non-atherosclerotic vasculopathies.\n* Provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Other determined etiology or established cause of the acute stroke or TIA: atrial fibrillation, mitral stenosis, mechanical valve, intracardiac thrombus or vegetation, dilated cardiomyopathy or ejection fraction \\\u003C30%, proximal extracranial carotid or vertebral stenosis \\>50%.\n* Contraindications to MRI, including MR-incompatible metallic implants (i.e. certain artificial cardiac valves, penile implants, other prosthesis), implanted electronic devices (i.e. pacemaker\u002Fdefibrillator, neurostimulators, cochlear implants), other potentially mobile ferromagnetic material (i.e. shrapnel, magnetic aneurysm clips), pregnancy (women in fertile age should have a negative pregnancy test), lactation, morbid obesity, and severe claustrophobia.","30 Years",{"count":323,"type":22},250,"An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.",[96,326,327,328],"TIA","Ischemic Stroke","Ischemic",[96],{"date":307,"type":41},{"date":332,"type":41},"2022-09-30",{"date":334,"type":22},"2027-09-30",{"name":47,"class":48},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":57,"sex":18,"minAge":114,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":347,"briefSummary":349,"conditions":350,"keywords":354,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":180},"100444435","phase-1-evaluation-of-oral-thc-and-cbd-in-men-and-women-100444435","NCT05067387","Evaluation of Oral THC and CBD in Men and Women","Evaluation of Oral THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women","O-TACOFS","Inclusion Criteria:\n\n* Male or non-pregnant and non-lactating females aged 21-55 years\n* Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening,\n* Not currently seeking treatment for their cannabis use\n* Have a Body Mass Index from 18.5 - 34kg\u002Fm2.\n* Able to perform all study procedures\n* Must be using a contraceptive (hormonal or barrier methods)\n\nExclusion Criteria:\n\n* Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine\n* Any other Axis I disorder\n* Report using other illicit drugs in the prior 4 weeks, other than cannabis.\n* Current use of any medications that may affect study outcomes\n* If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and \u002F or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.\n* Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.\n* History of an allergic reaction or adverse reaction to cannabis is exclusionary.\n* History of respiratory illness or current respiratory illness\n* Currently enrolled in another research protocol\n* Not using a contraceptive method (hormonal or barrier methods)\n* The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.","55 Years",{"count":346,"type":22},22,[348],"PHASE1","The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.",[351,352,353],"Drug Abuse","Intoxication by Drug","Impairment",[355,356,357,353],"THC","CBD","Intoxication",{"date":307,"type":41},{"date":360,"type":22},"2026-07-15",{"date":362,"type":22},"2028-06-15",{"name":47,"class":48},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":23,"phases":374,"briefSummary":375,"conditions":376,"keywords":379,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":180},"100643145","ucla-magnesium-formulation-athlete-study-100643145","NCT07640685","UCLA Magnesium Formulation Athlete Study","Effects of Magnesium Glycinate and Magnesium L-Threonate on Sleep, Recovery, and Performance in Collegiate Athletes","Mg-Form","Inclusion Criteria:\n\n* Age 18 to 35 years.\n* Current UCLA varsity athlete.\n* Actively training or competing during the study period.\n* Willing to wear WHOOP or a study-approved wearable device continuously during baseline and treatment periods if wearable data are used.\n* Willing to take assigned study capsules nightly for 28 days.\n* Willing to complete brief daily REDCap surveys and weekly adherence\u002Fsafety check-ins.\n* Able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Current magnesium supplementation without completion of an appropriate washout before baseline.\n* Current investigational drug or investigational supplement use.\n* Current use of prescription or over-the-counter sleep medications unless reviewed and permitted by the study clinician.\n* Diagnosed sleep disorder that, in the investigator's judgment, would confound outcomes or increase risk.\n* Significant kidney disease or another medical condition that may increase risk with magnesium supplementation.\n* Known intolerance or allergy to magnesium glycinate, magnesium L-threonate, placebo, or inactive study ingredients.\n* Use of medications with clinically relevant magnesium interactions unless reviewed and permitted by the study clinician.\n* Any other condition that, in the investigator's judgment, would make participation unsafe, compromise voluntary consent, or prevent valid outcome assessment.","35 Years",{"count":116,"type":22},[25],"This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. WHOOP or study-approved wearable data will be used to evaluate sleep efficiency, total sleep time, sleep consistency, heart rate variability, resting heart rate, and recovery metrics. Baseline and final testing will assess selected reaction and physical performance outcomes. The primary outcome is change in WHOOP-derived sleep efficiency from baseline week to final treatment week.",[377,378,274],"Athletic Performance","Recovery",[380,381,382,383,384,385,386,387,388,389],"magnesium glycinate","magnesium L-threonate","collegiate athletes","sleep duration","athlete recovery","WHOOP","heart rate variability","reaction time","placebo-controlled trial","dietary supplement","2026-06-05",{"date":307,"type":41},{"date":393,"type":22},"2026-07",{"date":395,"type":22},"2027-06",{"name":47,"class":48},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":245,"phases":4,"briefSummary":406,"conditions":407,"keywords":415,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":180},"100630260","fnirs-for-disorders-of-consciousness-100630260","NCT07485361","fNIRS for Disorders of Consciousness","Functional Near-infrared Spectroscopy in Disorders of Consciousness: Protocol Testing and Pilot in Neuro-ICU Setting","Inclusion Criteria:\n\nHealthy Control Participants:\n\n* Age 18 years or older\n* Proficient in English language\n* Intact cognition\n* Montreal Cognitive Assessment (MoCA) score \\> 26\n\nDoC Patients:\n\n* Age 18 years or older\n* Proficient in English language\n* Surrogate decision maker available\n* Admission to the intensive care unit within 28 days\n* Documented Glasgow Coma Scale (GCS) score\n* Auditory Function subscale score ≥1 on the Coma Recovery Scale-Revised (CRS-R)\n\nExclusion Criteria:\n\nHealthy Control Participants:\n\n* Known baseline hearing impairment without available hearing aids\n* Neurological or psychiatric history\n\nDoC Patients:\n\n* Known baseline hearing impairment without available hearing aids\n* Inability to obtain informed consent\n* Extensive bilateral frontal injury on available imaging (CT\u002FMRI)\n* Patients who have undergone craniectomy surgery\n* IV sedation in the past 24 hours\n* Absent auditory startle response (\\\u003C1 from Auditory Function subscale score of CRS-R)",{"count":405,"type":22},55,"The goal of this observational study is to learn whether functional near-infrared spectroscopy (fNIRS) can measure brain activity in healthy adults and in people with disorders of consciousness (DoC) in the neuro-intensive care unit (Neuro-ICU). DoC include conditions such as coma and minimally conscious state that occur after severe brain injury. These conditions make it difficult to assess a person's level of awareness because many clinical tests rely on observable behaviors such as speaking or moving, which are commonly impaired after brain injury.\n\nThe main questions the study aims to answer are:\n\n* Can fNIRS detect changes in brain activity in healthy adults when they receive sensory stimulation or perform mental tasks?\n* Can the same fNIRS protocol be used in patients with disorders of consciousness in the Neuro-ICU to measure brain responses and determine whether the method is feasible in this clinical setting?\n\nThe investigators will first study healthy adult volunteers to establish baseline brain responses and determine which tasks produce the most reliable signals. The protocol will then be applied to patients with disorders of consciousness admitted to the Neuro-ICU.\n\nParticipants will take part in a single research session lasting about 30 to 45 minutes while wearing the lightweight fNIRS headband that measures brain oxygen levels using near-infrared light. During the session, participants will:\n\n* Wear a non-invasive fNIRS headband placed on the forehead\n* Receive gentle sensory stimulation (for example, compression devices on the legs or hands)\n* Listen to sounds or spoken sentences\n* Perform guided mental tasks such as imagining walking through their home or imagining moving a limb\n\nThe study does not test a treatment and will not change medical care. The goal is to determine whether fNIRS can safely and reliably measure brain activity at the bedside and provide preliminary information that may help guide future research on improving the assessment of consciousness after brain injury.",[408,409,410,411,412,413,414],"Disorders of Consciousness Due to Severe Brain Injury","Disorders of Consciousness","Coma","Minimally Conscious State","Unresponsive Wakefulness Syndrome","Brain Injury","TBI Traumatic Brain Injury",[416,417,418,419,420,421],"Functional Near-Infrared Spectroscopy","Neurocritical Care","Functional Neuroimaging","Neuro Intensive Care Unit","Neurovascular Coupling","Consciousness Assessment","2026-06-04",{"date":424,"type":41},"2026-06-08",{"date":426,"type":41},"2026-05-01",{"date":428,"type":22},"2026-12",{"name":47,"class":48},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":58,"minAge":19,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":180},"100586470","phase-4-peace-trial-postpartum-evaluation-of-antihypertensive-cessation-and-efficacy-100586470","NCT06915792","PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy","Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PEACE): A Randomized Controlled Trial Comparing Oral Labetalol and Oral Extended-Release Nifedipine for Managing Postpartum Hypertension","PEACE","Inclusion criteria:\n\nAge ≥18 years Delivery at study institution at ≥28 weeks gestation Postpartum SBP \\> 150 and\u002For DBP \\> 100 OR 2 or more SBP \\> 140 and\u002For DBP \\> 90 within a 24-hour period Require initiation of an oral antihypertensive medication during postpartum hospital stay or within 7 days of discharge Treating obstetric team amenable to starting either study medication\n\nExclusion criteria:\n\nTreated with oral antihypertensive medications prior to delivery Known allergies or contraindications to nifedipine or labetalol History of moderate persistent to severe asthma, chronic obstructive pulmonary disease, heart failure, or greater than first-degree atrioventricular heart block Unable to provide written informed consent in English","64 Years",{"count":440,"type":22},110,[442],"PHASE4","This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.",[445],"Postpartum Hypertension (PPHT)",[447],"postpartum hypertension, blood pressure control, labetalol, nifedipine, antihypertensive therapy, pregnancy hypertension, maternal health, randomized controlled","2026-06-03",{"date":390,"type":41},{"date":451,"type":41},"2025-06-01",{"date":453,"type":22},"2027-10-31",{"name":47,"class":48},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":462,"maxAge":344,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":180},"100485204","evaluating-tdcs-brain-stimulation-in-depression-using-mri-100485204","NCT05598034","Evaluating tDCS Brain-stimulation in Depression Using MRI","Optimization of tDCS Brain Network Engagement in Depression","Inclusion Criteria:\n\n1. Age between 20 to 55 years, inclusive\n2. Gender: all\n3. Race\u002Fethnicity: all races and ethnic groups\n4. Capacity to provide informed consent\n5. Hamilton Rating Scale for Depression score of ≥17 and \\\u003C24, with or without symptoms of anxiety.\n6. Treatment naïve or on a stable standard antidepressant regimen (including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MOAIs) or tricyclic's (TCAs)) with no change in treatment 6-weeks prior to and during the tDCS intervention.\n7. Work at UCLA or live within 1-hr driving distance of UCLA\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Non-English speaking (due to scales administered)\n3. Substance Use Disorder within last 12 months\n4. Neurological condition associated with brain abnormalities (e.g., traumatic brain injury; recent stroke, tumor)\n5. Any contraindication to tDCS (e.g., skin disease or treatment causing irritation)\n6. Any condition that would contraindicate scanning (metal implants, claustrophobia or a breathing or movement disorder)\n7. Currently receiving any form of psychotherapy\n8. Change in antidepressant medication within 6-weeks of starting the trial\n9. Severe or treatment resistant depression - HAMD scores \\> 24 and a history of a major depressive episode lasting \\>2- years or failure to 2 or more antidepressant trials in the current index episode\n10. Any neuromodulation therapy (e.g., ECT, rTMS, DBS, VNS or tDCS) within the last 3-months\n11. Current or past (within the last 1-month) use of anticonvulsants, lithium, psychostimulant, dexamphetamine\n12. Current use of decongestants or other medication previously shown to interfere with cortical excitability\n13. Diagnosis: Schizophrenia Axis I disorder, or dementia of any type\n14. Bipolar I disorder (due to possible risk of mania and because lithium and anticonvulsants are excluded).\n15. On regular benzodiazepine medication that it is not clinically appropriate to discontinue for the 2-week duration of the trial\n16. Depression related to serious medical illness (i.e., mood disorder due to general medical condition) 17. Actively suicidal as defined by a score of 4 on item 3 of HAMD","20 Years",{"count":464,"type":22},144,[25],"Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific scalp locations and using a 9-volt battery to cause a small amount of electricity to pass through parts of the brain. Depending on the direction of electrical flow, tDCS can make brain cells (neurons) more likely or less likely to generate their own electrical signals. When evaluated as a treatment, tDCS is typically done in daily sessions over a period of two weeks.\n\nOne of the challenges of tDCS is to work out the best possible positioning of electrodes and direction of electricity flow to gradually cause lasting changes in brain activity in ways that might be expected to improve depression. To address this challenge, the investigators are using MRI to take pictures of the brain during tDCS. This data will help us better understand the short-term effects of tDCS in depression and help us learn how to customize future treatments to cause a lasting beneficial response.\n\nPatients with depression between the ages of 20-55 years are eligible to take part in this research. Potential participants will undergo:\n\n1. An assessment to confirm eligibility. This will take place over a secure videoconference call lasting no more than 3 hours.\n2. Two in-person study visits lasting 30 min and 2-1\u002F2 hours respectively. In the first visit, the investigators will use the MRI to take a picture of the brain and head structure to determine appropriate locations for placing the tDCS electrodes at the start of the second visit. Following electrode placement, an MRI scan will be performed to take pictures of the brain during tDCS. Depending on the study arm,\n\n   1. Participants may receive 'active' or 'sham' tDCS. The 'sham' condition is identical to the 'active' tDCS in every way except that it involves minimal tDCS and is designed to help rule out effects unrelated to the administered tDCS electricity.\n   2. Participants may also be asked to perform a mental task during MRI.",[468],"Major Depressive Disorder",[470,471,472],"Transcranial Direct Current Stimulation (tDCS)","MRI","Major Depression",{"date":424,"type":41},{"date":475,"type":41},"2022-10-20",{"date":477,"type":22},"2028-05-01",{"name":47,"class":48},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":494,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":505,"locationsCount":4},"100642885","phase-2-thcv-treatment-for-smokers-100642885","NCT07636356","THCV Treatment for Smokers","Development of Tetrahydrocannabivarin as a Treatment for Smokers","Inclusion Criteria:\n\n1. Be between the ages of 21 and 65;\n2. Smoke 10 or more combustible cigarettes per day;\n3. Have fewer than 3 months of smoking abstinence in the past year;\n4. Has self-reported ≥10 lifetime uses of cannabis products;\n5. Have self-reported recent (past 3-month) use of cannabis products;\n6. Agree to abstain from all other cannabinoid use during the study;\n7. Agree to abstain from all other medication use during the study, other than methods of birth control as listed in inclusion criteria for female participants;\n8. Agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile: oral contraceptives, Contraceptive sponge, patch, double barrier, intrauterine contraceptive device, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, hormonal vaginal contraceptive ring, complete abstinence from sexual intercourse.\n\nExclusion Criteria:\n\n1. Have current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine;\n2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any other psychotic disorder;\n3. Have a score of 3 or greater on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or anytime during study participation;\n4. Have a positive urine screen for any substances, including cannabis\n5. Have a breathalyzer reading above 0.000 g\u002Fdl;\n6. Be pregnant, nursing, or planning to become pregnant while taking part in the study;\n7. Have a medical condition that may interfere with safe study participation;\n8. Have clinically significant abnormalities on the EKG;\n9. Have evidence of renal impairment, defined by an eGFR value of \\\u003C90 ml\u002Fmin;\n10. Have evidence of hepatic impairment, defined by a score of ≥5 points on the Child-Pugh assessment of liver function;\n11. Exceed Grade 2 laboratory or vital sign abnormalities, based on FDA Guidance Document \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\";\n12. Have past month use of cannabis or cannabis products;\n13. Have past month use of electronic nicotine delivery system (ENDS);\n14. Have use of any medications (other than methods of birth control as listed in inclusion criteria for female participants) within 14 days or 5 half-lives (whichever is longer) prior to study drug administration, and throughout the study, including medication for smoking cessation, any prescription, OTC, dietary supplements, herbal products, or vitamins;\n15. Have any other circumstances that, in the opinion of the investigators, would not be a good fit for study participation.","65 Years",{"count":488,"type":22},32,[118],"This study will randomize 32 non-treatment-seeking individuals who smoke cigarettes daily into a randomized, crossover, double-blind, placebo-controlled study testing the safety, tolerability, and initial efficacy of Δ9-tetrahydrocannabivarin (Δ9-THCV).",[492,493],"Tobacco Use Disorder","Smoking Cessation",[495,496,497,498,499],"smoking cessation","tobacco use disorder","cigarette smoking","THCV","Tetrahydrocannabivarin","2026-06-02",{"date":305,"type":41},{"date":393,"type":22},{"date":504,"type":22},"2028-05-31",{"name":47,"class":48},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":58,"minAge":19,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":520,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":536,"leadSponsor":538,"locationsCount":180},"100641229","phase-4-suzetrigine-for-opioid-sparing-postoperative-analgesia-following-transvaginal-pelvic-reconstructive-surgery-100641229","NCT07600697","Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Undergoing elective transvaginal pelvic reconstructive surgery at UCLA with planned same-day discharge or 23-hour observation.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Chronic opioid use.\n* Liver failure.\n* End-stage renal disease (ESRD).\n* Chronic pain syndromes, including:\n\nFibromyalgia Interstitial cystitis Chronic pelvic pain\n\n* Contraindication to acetaminophen or ibuprofen.\n* Use of strong CYP3A4 inhibitors within 7 days prior to surgery or anticipated need during the treatment period.",{"count":513,"type":22},120,[442],"Suzetrigine is a selective NaV1.8 inhibitor that provides peripheral analgesia without opioid-related CNS effects. This single-center stepped-wedge randomized clinical trial evaluates whether a suzetrigine-based postoperative analgesic regimen provides non-inferior pain control compared with standard opioid-inclusive care following transvaginal pelvic reconstructive surgery. The study will enroll 120 participants and assess pain, opioid consumption, adverse events, and functional recovery.",[517,518,519],"Pelvic Organ Prolapse (POP)","Stress Urinary Incontinence (SUI)","Postoperative Pain",[521,522,523,524,525,526,527,528,529,530,531,532],"Suzetrigine","NaV1.8 Inhibitor","Non-opioid analgesic","pelvic reconstructive surgery","transvaginal surgery","postoperative pain","opioid-sparing analgesia","multimodal pain management","pelvic organ prolapse","randomized clinical trial","stepped-wedge design","phase 4 trial","2026-05-29",{"date":500,"type":41},{"date":38,"type":22},{"date":537,"type":22},"2028-07-01",{"name":47,"class":48},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":57,"sex":58,"minAge":19,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":553,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":563},"100607488","phase-2-evaluation-of-antimicrobial-prophylaxis-to-prevent-syphilis-in-pregnancy-in-patients-at-risk-in-rio-de-janeiro-brazil-100607488","NCT07189208","Evaluation of Antimicrobial Prophylaxis to Prevent Syphilis in Pregnancy in Patients at Risk in Rio de Janeiro, Brazil","PRESERvE","Inclusion Criteria:\n\n1. Uncomplicated, viable pregnancy\n2. Elevated risk for syphilis acquisition (one or more of the following):\n\n   1. Prior history of STIs last 3 years\n   2. HIV infection\n   3. Age \\\u003C 21 years\n   4. In a sexual partnership of \\\u003C 3 mo., or \\> 3 sexual partners in the last 6 mo.\n   5. Late initiation of prenatal care (\\> 14 weeks of pregnancy)\n   6. Residence in area where syphilis prevalence is 10% or higher.\n3. Ability to provide written informed consent\n4. No allergy to penicillin\n5. Prenatal care at one of the sites participating in the study\n6. Ongoing sexual activity during study period.\n7. Negative rapid treponemal test at baseline.\n\nExclusion Criteria:\n\n1. Non-viable pregnancy\n2. Very high risk pregnancy\n3. Inability to provide written informed consent\n4. Allergy to penicillin\n5. Positive rapid treponemal test at baseline\n6. Lack of sexual activity during study period.\n7. Any persisting coagulation disorder that would contraindicate IM injections.","45 Years",{"count":548,"type":22},500,[118],"The goal of this clinical trial is to learn if benzathine penicillin works to prevent maternal syphilis. It will also learn about the safety of benzathine penicillin. The main questions it aims to answer are:\n\n* Does benzathine penicillin lower the rate of syphilis in pregnancy?\n* What medical problems do participants have when taking benzathine penicillin? Researchers will compare benzathine penicillin to routine care to see if benzathine penicillin works to prevent syphilis.\n\nParticipants will:\n\n* Take benzathine penicillin or receive routine care during the third trimester of pregnancy\n* Visit the clinic once a month for injections and tests\n* Report any reactions to benzathine penicillin to the study team",[552],"Congenital Syphilis",[554],"congenital syphilis","2026-05-28",{"date":557,"type":41},"2026-06-01",{"date":559,"type":41},"2025-09-24",{"date":561,"type":22},"2030-07-31",{"name":47,"class":48},4,{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":18,"minAge":572,"maxAge":114,"enrollmentInfo":573,"targetDuration":4,"studyType":245,"phases":4,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":180},"100464572","inflammatory-and-glutamatergic-mechanisms-of-sustained-threat-in-adolescents-with-depression-100464572","NCT05329441","Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression","Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression: Toward Predictors of Treatment Response and Clinical Course","TIGER","Inclusion Criteria:\n\n* All sexes and genders\n* All ethnicities\n* Ages 14-21\n* Postpubertal (Tanner stage \\> 3)\n* No medications that will interfere with the study (including antidepressants, mood stabilizers, hormone supplements, steroids, etc.) for at least 2-6 weeks (depending on exact medication)\n* Currently being seen by a clinician who will treat the participant with fluoxetine or escitalopram\n* The ability to provide assent, understand, and complete all study procedures\n* Caregiver consent (if applicable)\n\nExclusion Criteria:\n\n* Primary mental health diagnosis other than a depressive disorder according to DSM-V\n* Any contraindications to MRI scanning, phlebotomy, or SSRI treatment\n* Stimulant usage\n* A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes\n* Any inflammatory conditions or use of anti-inflammatory medications that may influence study findings\n* Any major neurological or developmental disorders which could impact the participant's ability to comply with study procedure\n* Meeting for current or lifetime criteria of mania or psychosis, diagnosis of bipolar disorder, or any substance use disorders\n* First-degree relative with current, past, or suspected mania or psychosis","14 Years",{"count":574,"type":22},160,"Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment non-response, TNR). The goal of this project is to recruit and assess 160 treatment-seeking depressed adolescents and test whether acute stress impacts peripheral levels of inflammation and downstream levels of glutamate in corticolimbic regions previously associated with depression, whether these stress-related biomarkers predict TNR to a 12-week trial of either fluoxetine or escitalopram, and whether these stress-related biomarkers predict 18-month clinical course.",[577],"Depression in Adolescence",[579,580],"depression","adolescence","2026-05-27",{"date":533,"type":41},{"date":584,"type":41},"2023-07-06",{"date":586,"type":22},"2028-04-30",{"name":47,"class":48},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":58,"minAge":19,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":596,"briefSummary":597,"conditions":598,"keywords":603,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":180},"100641011","measuring-pelvic-floor-muscle-fitness-before-and-after-treatment-100641011","NCT07605598","Measuring Pelvic Floor Muscle Fitness Before and After Treatment","Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain Before and After Myofascially-Directed Therapies","Inclusion Criteria:\n\nWomen over 18 years of age\n\nPelvic Pain for more than 3 months\n\nReport an average daily pain intensity score of at least 4 on a 0 to 10 scale\n\nPalpable trigger\u002Ftender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam\n\nWilling to refrain from new clinical treatment that may affect pain during the study period\n\nExclusion Criteria\n\nInability to participate in clinic visits\n\nPrior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®) in the past 6 months\n\nActive UTI or vaginal infection\n\nPregnancy or childbirth in the past 12 months, currently planning a pregnancy\n\nIllicit Drug addiction\u002Fregular use of controlled substances (including marijuana use in the past 2 weeks or during the study period)\n\nPelvic floor physical therapy in the past 3 months\n\nMalignancy or other serious medical condition (e.g., poorly controlled diabetes \\[HgA1c \\> 8\\], chronic renal disease \\[GFR \\\u003C30\\], neurologic or rheumatic disease)\n\nDiagnosed with an alternate cause of pelvic pain (e.g., ulcerative interstitial cystitis, vestibulodynia, vulvar dermatoses, dysmenorrhea)\n\nUrinary retention with a PVR \\>150 mL\n\nGreater than stage 3 pelvic organ prolapse\n\nIndwelling vaginal devices (e.g., pessary, contraceptive ring. Not including Mirena IUD) that cannot be removed for the study\n\nInability to sign an informed consent, fill out questionnaires, or complete study interviews",{"count":513,"type":22},[25],"This study is being done to better understand and improve treatment for myofascial pelvic pain, a common cause of long-lasting pelvic pain in women. Myofascial pelvic pain is related to tight or dysfunctional pelvic floor muscles and can cause pain as well as bladder, bowel, and sexual problems. Current clinical evaluations mostly rely on physical examination and patient-reported symptoms and do not fully measure how the pelvic floor muscles are functioning.\n\nThe purpose of this study is to measure pelvic floor muscle function using a noninvasive imaging method called near-infrared spectroscopy, or NIRS. This method measures changes in muscle blood flow and oxygen levels during muscle contraction and relaxation. The study will examine whether pelvic floor muscle function improves after different treatments and whether these physiologic changes are associated with improvements in pain and symptoms.\n\nThe study will enroll 120 adult women who have had pelvic pain for at least three months and have pelvic floor muscle tenderness on examination. Participants will be randomly assigned to one of three groups: education with relaxation exercises, pelvic floor physical therapy focused on myofascial release, or vaginal medication used to help relax pelvic floor muscles.\n\nParticipants will take part in four study visits over a six-month period. During these visits, they will complete questionnaires about pain and pelvic symptoms, undergo pelvic floor examinations, and have pelvic floor muscle imaging using the NIRS device while performing brief muscle contractions and relaxations. Some visits will also include collection of blood, urine, and vaginal samples to measure inflammation.\n\nThe information gained from this study may help improve the diagnosis and treatment of myofascial pelvic pain by providing objective measures of pelvic floor muscle function and identifying which treatments are most effective for different patients.",[599,600,601,602],"Myofacial Pain","Pelvic Pain","Myofascial Pelvic Pain","Chronic Pelvic Pain",[604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622],"myofascial pelvic pain","chronic pelvic pain","pelvic floor muscle dysfunction","pelvic floor myalgia","pelvic floor hypertonicity","Near-infrared spectroscopy","NIRS imaging","Pelvic floor muscle oxygenation","Pelvic floor muscle blood flow","Pelvic floor muscle fitness","Pelvic floor physical therapy","Myofascial release therapy","Pelvic floor relaxation therapy","Intravaginal diazepam","Intravaginal baclofen","Pelvic floor muscle relaxation medication","Women's pelvic pain","Noninvasive pelvic floor assessment","Pelvic floor imaging","2026-05-21",{"date":625,"type":41},"2026-05-26",{"date":627,"type":22},"2026-09-01",{"date":629,"type":22},"2029-07-01",{"name":47,"class":48},{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":643,"conditions":644,"keywords":646,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":563},"100588280","ultrasound-stimulation-for-patients-in-a-disorder-of-consciousness-100588280","NCT06939348","Ultrasound Stimulation for Patients in a Disorder of Consciousness","Safety and Efficacy of Thalamic Focused Ultrasound Stimulation (tFUS) for Promoting Recovery After Severe Traumatic Brain Injury","tFUS","Inclusion Criteria:\n\n1. Diagnosis of DoC, following international guidelines, as assessed with the CRS-R.\n2. Prolonged status (\\>28days post-injury)\n3. If on a psychotropic medication regimen, that regimen will be stable for at least 4 weeks prior to entry to the study and the patient will be willing to remain on a stable regimen during the protocol.\n4. legally authorized representative available to consent for the patient to participate in the study\n\nExclusion Criteria:\n\n1. History of neurological disorder (other than the brain injury).\n2. Metal implant or other condition precluding safe entry in the MR-environment.\n3. Manifest continuous spontaneous movement (which would prevent safe\u002Fsuccessful imaging).\n4. Participation in another concurrent clinical trial.\n5. Need for mechanical ventilation.\n6. Craniotomy (no bone flap).\n7. Cranioplasty spanning the left temporal bone window.","79 Years",{"count":641,"type":22},60,[25],"The overall aim of this study is to develop an intervention that can help recovery in patients surviving severe brain injury but failing to fully recover. In particular, this multicenter project aims to (1) establish short-term efficacy of tFUS as a therapeutic to promote recovery in patients with prolonged DoC as compared to sham treatment, (2) establish dose-related safety and efficacy of tFUS as a therapeutic intervention in prolonged DoC patients and (3) explore preliminary predictors and biomarkers of susceptibility and response to thalamic sonication.",[645,408],"Consciousness Disorders",[647,648,411,649,650,651,652,653,654,655],"Disorder of Consciousness","Vegetative State","Minimally Conscious State Plus","Minimally Conscious State Minus","Traumatic Brain Injury","CVA (Cerebrovascular Accident)","Anoxia, Brain","Thalamic Infarction","Coma; Prolonged","2026-05-18",{"date":658,"type":41},"2026-05-22",{"date":660,"type":41},"2025-04-26",{"date":662,"type":22},"2028-09-29",{"name":47,"class":48},{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":668,"acronym":4,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":18,"minAge":188,"maxAge":670,"enrollmentInfo":671,"targetDuration":4,"studyType":23,"phases":673,"briefSummary":674,"conditions":675,"keywords":677,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":180},"100579983","the-stop-hpv-scale-up-study-100579983","NCT06831383","The STOP-HPV Scale Up Study","Inclusion Criteria:\n\n* Patient of participating practice\n* Well child care visit during the 12-month intervention period\n* No prior dose of HPV vaccine at the time of the well child care visit\n* Age-eligible\n\nExclusion Criteria:\n\n* Prior dose of HPV vaccine","17 Years",{"count":672,"type":22},100000,[25],"Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost effectiveness of two potentially scalable implementation strategies (based on prior work) to increase the initiation of HPV vaccine against a usual care (control) arm. The intervention arms are 1) online provider communication training only (\"STOP-HPV-Online\" and 2) online provider communication training plus a Learning Collaborative, with performance feedback, attended by practice leads (\"STOP-HPV-LC).\n\ncer-related costs. It is recommended at ages 11-12 years routinely but can be given starting at ages 9-10 years. Despite having an effective vaccine, HPV vaccine initiation\u002Fcompletion rates in the U.S. were only at 76.8%\u002F61.4% respectively in 2023 among 13-17 year olds; these rates are lower than the other recommended adolescent vaccines. Two key barriers are 1) suboptimal clinician communication to address parental concerns and 2) ineffective office systems causing missed vaccine opportunities.",[676],"Human Papilloma Virus Vaccine",[678,679],"Human Papillomavirus Vaccination","Practice-based improvement",{"date":681,"type":41},"2026-05-19",{"date":683,"type":41},"2026-03-30",{"date":685,"type":22},"2027-04-19",{"name":47,"class":48},{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":691,"acronym":4,"eligibilityCriteria":692,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":693,"enrollmentInfo":694,"targetDuration":4,"studyType":23,"phases":696,"briefSummary":698,"conditions":699,"keywords":701,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":710,"leadSponsor":712,"locationsCount":180},"100640609","early-phase-1-open-label-study-for-the-use-of-low-intensity-focused-ultrasound-for-essential-tremor-100640609","NCT07599592","Open Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor","Inclusion Criteria:\n\n1. Confirmed clinical diagnosis of ET\n2. Isolated tremor syndrome, at least 3 years duration\n3. Subjective complaint of tremor assessed and validated by physician\n4. Must be willing to comply with the study protocol\n5. English Proficiency\n6. At least 18 years of age\n7. At most 90 years of age\n\nExclusion Criteria:\n\n1. Severe microvascular disease or structural brain lesions equivalent to Fazekas scale of 3 or higher in the periventicular or deep white matter.\n2. Subjects on blood thinning medications (e.g. Eliquis)\n3. Recent stroke (within the last 6 months)\n4. Implanted electrodes (e.g. DBS) in brain\n5. History of aneurysm\n6. History of cranial trauma resulting in fracture or traumatic brain injury\n7. Subjects who are unable to cooperate with the testing.\n8. Subjects who lack capacity to consent\n9. Subjects with severe cardiac disease, increased intracranial pressure, or using a transcutaneous electrical nerve stimulation (TENS) unit.\n10. Severe cardiac disease will be defined as any of the following:\n\n    i) History of myocardial infarction within the past 6 months ii) Diagnosis of congestive heart failure with NYHA Class III or IV symptoms iii) History of unstable angina, life-threatening arrhythmias, or use of an implantable cardioverter-defibrillator (ICD) iv) Uncontrolled hypertension (SBP \\>180 mmHg or DBP \\>110 mmHg) despite medication v) Any condition judged by the study physician to place the subject at increased risk from study participation\n11. Subjects with implanted medical devices\n12. Subjects with a history of seizure disorder.\n13. Subjects with contraindications to enter MRI environment\n14. Subjects with a history of substance abuse.\n15. Subjects who are currently pregnant. This will be verified by a urine test prior to beginning the study.","90 Years",{"count":695,"type":22},20,[697],"EARLY_PHASE1","This open-label pilot study will evaluate the safety, tolerability, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound pulsation (LIFUP) targeting the ventral intermediate nucleus (Vim) of the thalamus in patients with Essential Tremor (ET). Twelve adults with clinically diagnosed ET will undergo six LIFUP treatment sessions over approximately two weeks using the BrainSonix BX Pulsar 1002 system. Tremor severity will be assessed using clinician-rated scales (TETRAS and FTM), patient-reported quality-of-life measures (QUEST), and objective accelerometry before and after treatment sessions, with additional follow-up visits at one and three months post-treatment. MRI scans will be performed at baseline and after the final treatment session to monitor safety. The study aims to characterize whether non-ablative focused ultrasound can safely and transiently modulate tremor-related thalamic circuits and provide preliminary evidence supporting future controlled trials of LIFUP for ET.",[700],"Essential Tremor",[702,637,703,704,705],"Brainsonix","Focused Ultrasound","Tremor","Movement Disorder","2026-05-14",{"date":708,"type":41},"2026-05-20",{"date":426,"type":41},{"date":711,"type":22},"2027-06-01",{"name":47,"class":48},""]